---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000573"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:56:33.657087+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO

## Summary
- Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.
- Total operating expenses fell to $31.0M from $46.2M; revenue down $27.3M due to pivot from infectious disease.
- Cash and equivalents $213.4M, runway beyond Q2 2028. Cash decreased $19.4M from Dec 2025.
- ARCT-032 CF Phase 2 study enrollment initiated; ARCT-810 OTC deficiency gets FDA clarity for pivotal pediatric path.
- Dennis Mulroy appointed CFO effective May 1, 2026; base salary $520k, options for 100k shares.

## SEC filing metadata
- accession: 0001193805-26-000573
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000573
- JSON: https://secwatch.observer/filing/0001193805-26-000573.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000573.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm
- Executive change
  Dennis Mulroy was appointed as Chief Financial Officer at Arcturus Therapeutics Holdings Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.